M-100907 Aventis

Current Opinion in Investigational Drugs

Volumn 2, Issue 1, 2001, Pages 123-132

  De Paulis, T ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMISULPRIDE; CLOZAPINE; CORTICOSTEROID; CORTICOSTERONE; DIZOCILPINE; DOPAMINE; FANANSERIN; GLEMANSERIN; HALOPERIDOL; KETANSERIN; MDL 100009; MDL 101860; MDL 105725; MDL 28161; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTENSIN; NORADRENALIN; OLANZAPINE; PAROXETINE; PROTEIN C FOS; QUETIAPINE; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SULPIRIDE; ZIPRASIDONE; ZOTEPINE;

ATTENTION DEFICIT DISORDER; AUTISM; CLINICAL TRIAL; CONSTIPATION; DOSE RESPONSE; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; HEADACHE; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PSYCHOSIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM;

ANIMALS; CLINICAL TRIALS; FLUOROBENZENES; HUMANS; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035154317     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. 2 receptor agonist
2. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pK(i) values
3. Pharmacological effects of MDL 11,939: A selective, centrally acting antagonist of 5-HT-2 receptors
4. Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats
5. 2 receptor antagonist MDL-100907 as a putative atypical antipsychotic: Behavioural, electophysiological and neurochemical studies
6. 3 mediated control of dopaminergic function
7. Excitation of interneurons in piriform cortex by 5-hydroxytryptamine: Blockade by MDL-100907, a highly selective 5-HT(2A) receptor antagonist
8. Immobilization of substrates in enzyme-catalyzed hydrolysis
9. 2A receptor antagonist, MDL-100907, increases dopamine efflux in the prefrontal cortex of the rat
10. Blockade of the discriminative stimulus effects of DOI by MDL-100,907 and the atypical antipsychotics, clozapine and risperidone
11. 2A receptors in antipsychotic activity
12. 2A receptors
13. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin-2 and dopamine-2 receptors
14. 2 receptors
15. Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor
16. 2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - Implications for psychosis
17. 2A receptors with positron emission tomography
18. Synthesis and biodistribution of (F-18)-MDL100907. A potent ligand for PET studies of 5HT-2A receptors
19. 5-HT modulation of auditory and visual sensorimotor gating: II effects of the 5-HT 2A antagonist MDL 100,907 on disruption of sound and light repulse inhibition produced by 5-HT agonists in Wistar rats
20. Inhibitory effects on the discriminative stimulus properties of D-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system?
21. HMR sets development priorities
22. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT(2A) antagonist with a favorable CNS safety profile
23. Involvement of 5-HT-2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212
24. 2A receptor ligand
25. Comparison of neurotensin responses to MDL 100,907, a selective 5HT(2A) antagonist, with clozapine and haloperidol
26. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice
27. 2 receptor subtype antagonists in rat and mouse models of anxiety
28. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells
29. 3H]MDL 100,907
30. Time course of 5-HT(2A) receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography
31. MK-801-induced hyperlocomotion: Differential effects of m100907, SDZ PSD 958 and raclopride
32. 2 antagonism differentially affects apomorphine- and amphetamine-induced stereotyped behavior
33. Down regulation of tyrosine hydroxylase in the rat locus coeruleus following chronic treatment with M100907
34. MK-801-induced hyperlocomotion: Differential effects of M100907, SDZ PSD 958 and raclopride
35. 2 agonist DOI: Effects of MDL 100,907, clozapine, risperidone and haloperidol
36. 2A receptors with carbon-11-MDL 100,907
37. M100907, a selective 5-HT(2A) receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro
38. Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat
39. Effects of hallucinogens on locomotor and investigatory actinity and patterns: Influence of 5-HT(2A) and 5-HT(2C) receptors
40. M100907, a highly selective 5-HT2A receptor antagonist and a potential atypical antipsychotic drug, facilitates induction of long-term potentiation in area CA1 of the rat hippocampal slice
41. Investigation of the CNS penetration of a potent 5-HT2a receptor antagonist (MDL-100,907) and an active metabolite (MDL-105,725) using in vivo microdialysis sampling in the rat
42. Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin(2A) receptor antagonist MDL 100,907
43. Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain
44. The selective 5-HT-2A receptor antagonists MDL 100,907 attenuates the behavioural and neurochemical effects of PCP in rodents
45. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice
46. 2A receptors in the subthalamic nucleus
47. Preliminary data indicate first in new class of schizophrenia drugs offers broad range of activity without side-effects of current therapies
48. Aventis aims to reap benefit from broader research and development pipeline
49. BT Alex Brown: Rhone Poulenc/Hoechst
50. Pan-Europe Pharmaceuticals: Pan-European pharmaceutical review
51. Aventis, new world leader in life sciences, launched today; Rhone-Poulenc shareholders overwhelmingly approve final steps of merger with Hoechst; Supervisory board members appointed; full listing on world stock exchanges on December 20
52. Disposition of M100907 in healthy men and women
53. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs
54. Neurotransmitter interactions in schizophrenia - Therapeutic implications
55. Pet studies of 5-HT2a receptors in vivo using MDL 100907
56. Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: Tests with subtype selective receptor ligands
57. SSRI's plus 5HT 2a antagonism compared to SSRI alone produces inverse effects on the firing activity of nonadrenergic neurons
58. Serotonin-glutamate interactions: A new target for antipsychotic drugs
59. 11C]MDL 100,907
60. High 5HT(2A) receptor occupancy in M100907-treated schizophrenic patients
61. Network interactions in schizophrenia - Therapeutic implications
62. In-vivo assessment of 5-HT(2A) and 5-HT(2C) antagonistic properties of newer antipsychotics
63. Pharmacological and molecular targets in the search for novel antipsychotics
64. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat
65. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: Importance of nucleus accumbens 5-HT(2A) sites for PCP-induced locomotion in the rat
66. Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice
67. 2 antagonists and the search for novel antipsychotic strategies
68. The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action
69. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia
70. 2A receptor antagonist, potentiates haloperidol-induced dopamine release in the rat medial prefrontal cortex but inhibits that in the nucleus accumbens
71. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
72. 2A antagonist, M100907, following single and multiple oral dosing in healthy volunteers
73. Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: A novel locus of antipsychotic drug action
74. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors
75. 11C]MDL 100907 labeled in two specific positions
76. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
77. 2A antagonists on inherited catalepsy in rats
78. NMDA-sensitive glutamate antagonism: A human model for psychoses
79. 2A and α1-adrenoreceptor antagonism
80. 2A receptor system
81. Serotonergic involvement in haloperidol-induced catalepsy
82. Serotonin-2A receptors are reduced in the planum temporale from subjects with schizophrenia
83. MDL 100,907: A selective 5-HT(2A) receptor antagonist for the treatment of schizophrenia
84. 2 receptors
85. 2A receptor antagonist MDL 100,907 on cocaine-induced c-Fos expression
86. 2 modulation of psychostimulant-induced facilitation of brain stimulation reward
87. 11C]labeled PET ligands
88. 18F]setoperone PET serotonin-2A receptor data in schizophrenia
89. 2A agonist models of psychosis?